Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding Inc

Eli Lilly said Monday it would pay $3.2 billion to acquire an innovator in oral treatments for chronic bowel diseases.

Eli Lilly Snaps Up Morphic At 79% Premium

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.

3 No-Brainer Stocks to Buy in July

Eli Lilly agrees to pay $57 a share for Morphic, or a 79% premium to the stock's closing price of $31.84 on Friday.

Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%.

Shares of Morphic Holding Inc. MORF, +0.03% rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. LLY, +1.83% in a cash deal valued at about $3.2 billion. Lilly's stock LLY, +1.83% tacked on 0.2% ahead of the open.

Morphic's stock rockets after $3.2 billion buyout deal with Eli Lilly

Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday.

Eli Lilly to acquire Morphic Holding for $3.2 billion

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

AT&T

abrdn Life Sciences Investors 

Verizon

Don't fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionary sectors — telecom and healthcare.

Recession Alert: Play Defense While Earning Up To 10% Yield

New obesity and Alzheimer's disease treatments are keeping Eli Lilly and Company (LLY) at the forefront of equities excellence.

Eli Lilly Remains an Equities Outlier

ASML Hld

Deckers Outdoor

MercadoLibre

MicroStrategy Incorporated

Mettler-Toledo

Several high-profile stock splits have occurred recently. First, Nvidia (NASDAQ: NVDA ) decided to implement a 10-for-1 stock split which took effect June 10.

7 High Priced Stocks That Would Benefit From a Stock Split

Novo Nordisk

A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

24/7 Insights Wall Street expectations for where Eli Lilly and Co.

Eli Lilly Stock Price Prediction: Where Will It Be in 1 Year

Zepbound and Mounjaro will add tens of billions in revenue to Eli Lilly's top line in the years ahead. But management is looking beyond those products and developing even more weight loss treatments.

Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation

Abbott Labs

Amgen

The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors.

The 3 Best Healthcare Stocks to Buy in July 2024

Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.

Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness

On Tuesday, the FDA approved Eli Lilly and Co's  LLY Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst

Eli Lilly (LLY) has received Food and Drug Administration (FDA) approval for its treatment for early symptomatic Alzheimer's after studies showed that the drug was able to slow the progression of the disease.

FDA Approves Eli Lilly's Alzheimer's Drug Kisunla

U.S. officials have approved another Alzheimer's drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

FDA approves a second Alzheimer's drug shown to delay cognitive decline

Harrow Health Inc

Longboard Pharmaceuticals

As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Crash This Quarter

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

Biogen

Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.

Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug

Eli Lilly's new Alzheimer's drug, Kisunla, shows promise with its unique treatment regimen and potential competitive advantages over Biogen's Leqembi. Despite challenges, Kisunla is priced aggressively at $32,000 per year, offering a potentially more cost-effective solution given its shorter treatment duration. Eli Lilly reported a 26% increase in revenue in Q1, driven by strong performances from its diabetes and obesity drugs.

Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval

The Food and Drug Administration (FDA) has approved Eli Lilly and Co's (NYSE:LLY) new Alzheimer's drug, donanemab, to be sold under the brand name Kisunla. This monoclonal antibody infusion, administered every four weeks, targets amyloid in the brain, a hallmark of Alzheimer's disease.

Eli Lilly's Alzheimer's drug receives FDA sign-off

Eli Lilly & Co (NYSE: LLY) received approval for its Alzheimer's drug from the Food & Drug Administration on Tuesday.  The development is significant as it expands treatment options for the neurological disorder that affects close to 7 million Americans.

Eli Lilly receives FDA approval for its Alzheimer's drug Kinsula

An Eli Lilly & Co. Alzheimer's drug won Food and Drug Administration approval Tuesday, capping the medication's bumpy ride through the U.S. regulatory process and adding a second new treatment option for patients in earlier stages of the disease.

Eli Lilly's Alzheimer's drug wins FDA approval

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

News for Eli Lilly Stock (LLY)